skip to Main Content


26-28 September

Seville, Spain

Dear Colleagues,

On behalf of The European Association for the Study of the Liver (EASL), it gives me great pleasure to invite you to join us at the EASL Non-Alcoholic Fatty Liver Disease (NAFLD) Summit. The meeting will be held on 26-28 September in Seville, Spain.

NAFLD is the leading cause of chronic liver disease, not only in Western countries, but also amongst many other developed and developing countries.

Indeed, in the US and Europe, nearly 40% of the population have NAFLD and approximately 20% are likely to develop progressive liver disease that leads to liver fibrosis and cirrhosis.

At EASL, we are committed to helping clinicians, researchers and students network with various stakeholders in the field of hepatology, providing the opportunity to share research and learn from peers across Europe and beyond.

NAFLD Summit attendees will learn and discuss new developments and challenges in NAFLD, including how the development of new therapies is urgently needed in this arena. To maximise exposure with attendees at the NAFLD Summit and enrich the meeting experience, companies are invited to participate as conference partners. Here, organisations can benefit from a variety of partnership packages, which include premium, bespoke and individual sponsorship and engagement opportunities.

Our dedicated team will provide you with all the support required to achieve and maximise your conference and communications objectives, ensuring a successful Summit and a smooth experience.

We look forward to welcoming you to the city of Seville in September.

Yours Sincerely,

Philip Newsome
EASL Secretary General

Why attend?
  • Most complete yearly review of the NAFLD/NASH topic
  • Quality guaranteed by EASL
  • Leading edge and provocative programme.
  • Return home with a different view on many clinical issues
Who should attend?
  • Hepatologists
  • Gastroenterologists
  • Diabetologists
  • Nutritionists
  • Public and population Health agencies
  • Big pharma and biotech industry
  • Regulatory agencies